Biolayer Interferometry for Crowded Protein Binding Analysis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for analyzing protein behavior in biological contexts fail to effectively account for non-specific interactions under non-ideal conditions, such as those found in vivo, where macromolecular crowding and complex solution environments affect protein function and binding equilibria.

Innovation Solution

A method using biolayer interferometry to determine the effect of non-specific interactions in simulated in vivo conditions by contacting a solution with a biologically relevant molecular crowding agent and a target molecule with a biosensor, allowing the target molecule to bind to a capture molecule and measuring the amount bound, with comparisons to control thresholds to distinguish between attractive and repulsive interactions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If protein concentration is increased to high values to simulate in vivo conditions, then the physiological relevance of the experiment is improved, but macromolecular crowding occurs causing non-linear binding behavior and deviation from ideal solution assumptions

Engineering Contradiction:

Improvephysiological relevanceVSAvoidbinding linearity

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent changes the concentration parameter from micromolar (ideal conditions) to millimolar (physiological conditions) to simulate in vivo environments. This parameter change enables the study of non-specific interactions and macromolecular crowding effects that are relevant to actual biological systems, while accepting the resulting non-linear binding behavior as informative rather than problematic

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the previously problematic macromolecular crowding effect into a beneficial feature by deliberately implementing high protein concentrations (e.g., 100 g/L albumin) to mimic physiological conditions. The non-specific interactions that were once considered experimental noise are now recognized as biologically relevant phenomena that provide insights into in vivo protein behavior

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Measurement precision

If non-specific interactions are included in the analysis to reflect biological reality, then the accuracy of in vivo prediction is improved, but the complexity of data interpretation increases due to deviation from simple binding models

Engineering Contradiction:

Improvein vivo prediction accuracyVSAvoiddata interpretation complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent applies partial action by focusing measurement on the specific protein-protein interaction of interest while acknowledging the presence of non-specific interactions through control experiments. Rather than attempting to model all interactions simultaneously, the method uses controls to distinguish specific from non-specific binding, simplifying data interpretation while maintaining biological relevance

Inventive Principle:

Principle #16Partial or excessive action

3Reliability

If controls for non-specific interactions are implemented to distinguish attractive and repulsive interactions, then the reliability of interaction classification is improved, but the experimental time and number of measurements increase

Engineering Contradiction:

Improveinteraction classification accuracyVSAvoidexperimental time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent performs preliminary control measurements with inert proteins or unrelated proteins before conducting the main interaction studies. These preliminary controls establish baseline non-specific interaction levels, allowing the main experiments to be interpreted relative to this baseline. This preliminary action prevents unnecessary repetition of control experiments and reduces overall experimental time

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a direct method to assess the impact of non-specific protein-protein interactions on specific biologically relevant interactions, enabling the identification of biomolecules better suited for in vivo conditions and potentially improving therapeutic efficacy by accounting for crowding effects.

Implementation Method 1

the surface of the biosensor comprises a capture molecule that specifically binds the target molecule

Methodology Applied

Scientific EffectSpecific binding: Adsorption

Implementation Method 2

determining an amount of the target molecule bound to capture molecule using biolayer interferometry

Methodology Applied

Scientific EffectBiolayer interferometry: Interference

Data Source

PatentUS11879896B2Therapeutic protein selection in simulated in vivo conditions

Publication Date: 2024.01.23 REGENERON PHARMACEUTICALS INC

AI summary

A method of determining the effect of non-specific interactions in simulated in vivo conditions is presently disclosed. The method includes (a) contacting a solution comprising a biologically relevant molecular crowding agent and a target molecule with a biosensor, wherein the surface of the biosensor comprises a capture molecule that specifically binds the target molecule; (b) allowing the target molecule to bind to the capture molecule; and (c) determining an amount of the target molecule bound to capture molecule using biolayer interferometry.